A Phase 3 Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer
Bladder Cancer Urothelial Carcinoma Urothelial Carcinoma Bladder Non-muscle invasive bladder cancer Low grade non-muscle invasive bladder cancer Intermediate risk non-muscle invasive bladder cancer NMIBC UGN-102 Mitomycin Transurethral resection of bladder tumors TURBT Carcinoma Urinary Bladder Neoplasms Carcinoma, Transitional Cell Mitomycins UGN-102 ± TURBT TURBT Alone
Lead Scientist at University of California Health
- Ramy Yaacoub, MD (uci)
Associate Clinical Professor, Urology.
- accepting new patients
- Start Date
- Completion Date
- UroGen Pharma Ltd.
- Phase 3
- Study Type
- Last Updated